title: Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan.
abstract: The serotonin receptor agonist triptan drugs (5-HT1B/1D receptor agonists) have been in use for over 20 years in the abortive management of migraine. Although clearly effective, their ability to produce vasoconstriction in cerebral and coronary arteries, thought to be mediated by their high affinity for the 5-HT1B receptor, has been a limitation to their use in certain patient populations. Variable potency triptan binding at the 5-HT1F receptor occurs in addition to binding at the 5-HT1B and 5-HT1D receptors. A more selective serotonin agonist without 5-HT1B-mediated vasoconstriction might prove efficacious yet safer. The 5-HT1F receptor has been targeted as a site of action for such a drug. In experimental models, 5-HT1F receptor agonists have been shown to block neurogenic inflammation and c-Fos expression in neural tissue and, as well, show no evidence of vasoconstriction in vascular tissue models in vitro. In clinical trials, efficacy in the abortive management of migraine has been established. Lasmiditan (LY573144), a selective 5-HT1F receptor agonist (K1=2.21 μM), showed efficacy in its primary endpoint, with a 2-hour placebo-subtracted headache response of 28.8%, though with frequent reports of dizziness, paresthesias, and vertigo. Study results support an emerging central neuronal mechanism of migraine pathophysiology. This review traces the history and use of 5-HT1F receptor agonists, now referred to as neurally acting anti-migraine agents in migraine management.
authors.affiliation: Department of Neurology, Brigham and Women's Faulkner Hospital, John R. Graham Headache Center, Boston, MA, USA.
authors.forename: Paul B
authors.initials: PB
authors.lastname: Rizzoli
keywords: 5-HT1F receptor; lasmiditan; migraine; serotonin; treatment; vasoconstriction
references.citation: Cephalalgia. 2002 Oct;22(8):633-58
references.pmid: 12383060
references.citation: Cephalalgia. 2010 Oct;30(10):1159-69
references.pmid: 20855361
references.citation: J Headache Pain. 2012 Jun;13(4):271-5
references.pmid: 22430431
references.citation: Cephalalgia. 2011 Jul;31(9):1061
references.pmid: 21511951
references.citation: CNS Spectr. 2003 Jun;8(6):446-9
references.pmid: 12858134
references.citation: Curr Opin Neurol. 2011 Jun;24(3):203-10
references.pmid: 21464715
references.citation: Lancet Neurol. 2012 May;11(5):405-13
references.pmid: 22459549
references.citation: Cephalalgia. 2010 Oct;30(10):1157-8
references.pmid: 20855360
references.citation: Trends Pharmacol Sci. 2011 Jun;32(6):352-9
references.pmid: 21459461
references.citation: Lancet. 2001 Oct 13;358(9289):1230-4
references.pmid: 11675061
references.citation: Cephalalgia. 2010 Oct;30(10):1170-8
references.pmid: 20855362
references.citation: J Headache Pain. 2009 Dec;10(6):395-406
references.pmid: 19795182
references.citation: Headache. 2003 Apr;43(4):376-88
references.pmid: 12656709
references.citation: Lancet. 2012 Dec 15;380(9859):2197-223
references.pmid: 23245608
references.citation: Headache. 2013 Mar;53(3):427-36
references.pmid: 23470015
references.citation: Lancet Neurol. 2012 May;11(5):383-4
references.pmid: 22459548
references.citation: Cephalalgia. 2005 Feb;25(2):124-31
references.pmid: 15658949
references.citation: Cephalalgia. 2003 Oct;23(8):776-85
references.pmid: 14510923